Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Humacyte (HUMA) Stock Price & Analysis
409 Followers
HUMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.96 - $6.62
Previous Close$6.42
Volume3.05M
Average Volume (3M)1.52M
Market Cap
$806.80M
Enterprise Value$741.58M
Total Cash (Recent Filing)$80.45M
Total Debt (Recent Filing)$57.51M
Price to Earnings (P/E)-6.4
Beta1.68
Next Earnings
Aug 09, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding119,084,353
10 Day Avg. Volume1,879,912
30 Day Avg. Volume1,516,806
Standard Deviation0.21
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)48.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.93
Forecast
1Y Price Target
$8.25Price Target Upside21.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Humacyte News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementThe approval of the Human Acellular Vessel is largely derisked due to encouraging clinical efficacy and safety, complemented by the FDA's Priority Review and the product's RMAT designation.
Market PotentialFresenius, the company's largest shareholder, has committed to adopt the Human Acellular Vessel as standard of care where appropriate, suggesting strong confidence in the product's market potential.
Regulatory MilestoneThe company's vascular trauma BLA submission has been accepted for review by the FDA and was also granted priority review, indicating a streamlined path towards potential approval.
Bears Say
Healthcare CostsTreatment of AV access complications in certain patient groups can lead to substantial Medicare costs, exceeding $30K in the first year.
Healthcare CostsSpecific high-risk subgroups, such as obese and diabetic women, may face even higher treatment costs, potentially reaching $91K in the first year.
Patient DemographicsFemales and African American patients with End-Stage Renal Disease have high rates of complications with current AV access treatments.
---
Ownership Overview
20.74% Insiders
4.01% Mutual Funds
9.59% Other Institutional Investors
65.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $1.96 and its highest was $6.62 in the past 12 months.
What is Humacyte’s market cap?
Currently, no data Available
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Aug 09, 2024 which is in 85 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on May 10, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.226 by -$0.064.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -$0.23.
How many shares outstanding does Humacyte have?
Humacyte has 119,084,350 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.226. Following the earnings report the stock price went up 3.982%.
Which hedge fund is a major shareholder of Humacyte?
Among the largest hedge funds holding Humacyte’s share is Clough Capital Partners L P. It holds Humacyte’s shares valued at 367K.
---
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (21.77% Upside)
$8.25 (21.77% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 82.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.71%
12-Months-Change
Fundamentals
Return on Equity
-195.68%
Trailing 12-Months
Asset Growth
-11.76%
Trailing 12-Months
Company Description
Humacyte
Alpha Healthcare Acquisition Corp is a blank check company.
---
HUMA Earnings Call
Q1 2024
0:00 / 0:00
---
HUMA Stock 12 Month Forecast
Average Price Target
$8.25
▲(21.77% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+39.29%
reiterated a buy rating 3 days ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +39.29% per trade.
---